Nancy Vitale serves as Director of the Company. Ms. Vitale has served as Managing Partner of Partners for Wellbeing, LLC, a human resource consulting firm, since April 2019. Previously, from September 2006 to July 2019, Ms. Vitale served in roles of increasing responsibility at Genentech, Inc., a biotechnology company acquired by Roche Holdings, Inc. in March 2009, most recently as Senior Vice President and Chief Human Resource Officer. Ms. Vitale also currently serves on the board of directors of Make-A-Wish America, a nonprofit foundation, and as an advisor to several private companies. Ms. Vitale received her B.B.A. from the University of Michigan and her M.B.A. from the Goizueta Business School of Emory University.
Nancy's mailing address filed with the SEC is C/O VOYAGER THERAPEUTICS, INC., 75 HAYDEN AVENUE, LEXINGTON, MA, 02421.
Over the last 9 years, insiders at Voyager Therapeutics Inc have traded over 22,599,571$ worth of Voyager Therapeutics Inc stock and bought 9,198,716 units worth 93,782,260$ . The most active insiders traders include Sanofi、Capital, Llc Eco R1、Biosciences Inc Neurocrine. On average, Voyager Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of 966,976$. The most recent stock trade was executed by Robin Swartz on 2 April 2024, trading 1,357 units of VYGR stock currently worth 13,407$.
voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.
Voyager Therapeutics Inc executives and other stock owners filed with the SEC include: